People on the Move
MYOS
MYOS Corporation, a young biotherapeutics company focused on muscle health, has appointed Wall Street veteran Christopher Pechock to its Board of Directors.
Pechock has worked for more than 25 years as an investment banker, buy-side and sell-side analyst, and private equity professional. He is currently Chairman of the Investment Committee of Matlin Patterson Global Advisers.
MYOS develops biologics to improve muscle function for patients with sarcopenia, cachexia and degenerative muscle diseases. The company owns MYO-T12(R), an inhibitor which speeds muscle growth and recovery by lowering levels of the natural regulatory protein myostatin.